無料プレビュー

United Therapeutics Corporation (UTHR) · NASDAQ Global Select

プロフィール

United Therapeutics is a public benefit corporation that develops and commercializes pharmaceutical therapies and organ-manufacturing technologies for rare and life-threatening diseases. The company markets five commercial pulmonary arterial hypertension (PAH) treatments in the U.S.—Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Adcirca—plus the Remunity and RemunityPRO infusion pumps and the oncology product Unituxin for neuroblastoma. The company also operates a regenerative medicine and xenotransplantation program to develop manufactured organ alternatives, and provides ex vivo lun

主要指標

株価: $532.78 (-2.24%)
時価総額: 226億ドル
PER（今期予想）: 20.3
PBR: 3.5
配当利回り: —
52週レンジ: $409.07 – $609.35
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-04 · 更新: 2026-10-09